title: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
authors.affiliation: University of California at Los Angeles, Los Angeles, USA. defurst@mednet.ucla.edu
authors.forename: D E
authors.initials: DE
authors.lastname: Furst
authors.forename: E C
authors.initials: EC
authors.lastname: Keystone
authors.forename: R
authors.initials: R
authors.lastname: Fleischmann
authors.forename: P
authors.initials: P
authors.lastname: Mease
authors.forename: F C
authors.initials: FC
authors.lastname: Breedveld
authors.forename: J S
authors.initials: JS
authors.lastname: Smolen
authors.forename: J R
authors.initials: JR
authors.lastname: Kalden
authors.forename: J
authors.initials: J
authors.lastname: Braun
authors.forename: B
authors.initials: B
authors.lastname: Bresnihan
authors.forename: G R
authors.initials: GR
authors.lastname: Burmester
authors.forename: F
authors.initials: F
authors.lastname: De Benedetti
authors.forename: T
authors.initials: T
authors.lastname: Dörner
authors.forename: P
authors.initials: P
authors.lastname: Emery
authors.forename: A
authors.initials: A
authors.lastname: Gibofsky
authors.forename: A
authors.initials: A
authors.lastname: Kavanaugh
authors.forename: B
authors.initials: B
authors.lastname: Kirkham
authors.forename: M H
authors.initials: MH
authors.lastname: Schiff
authors.forename: J
authors.initials: J
authors.lastname: Sieper
authors.forename: N
authors.initials: N
authors.lastname: Singer
authors.forename: P L C M
authors.initials: PL
authors.lastname: Van Riel
authors.forename: M E
authors.initials: ME
authors.lastname: Weinblatt
authors.forename: M H
authors.initials: MH
authors.lastname: Weisman
authors.forename: K
authors.initials: K
authors.lastname: Winthrop
mesh_terms: D000069594:Abatacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000069594:Abatacept; C502936:tocilizumab